Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen

PHASE3CompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
HIV Infections
Interventions
DRUG

Videx EC

DRUG

Epivir

DRUG

Sustiva

Trial Locations (48)

Unknown

Local Institution, Little Rock

Local Institution, Beverly Hills

Local Institution, Fountain Valley

Local Institution, Long Beach

Local Institution, Los Angeles

Local Institution, San Diego

Local Institution, San Francisco

Local Institution, Tarzana

Local Institution, West Hollywood

Local Institution, Denver

Local Institution, Norwalk

Local Institution, Washington D.C.

Local Institution, Atlantis

Local Institution, Daytona Beach

Local Institution, Fort Lauderdale

Local Institution, Jacksonville

Local Institution, Miami

Local Institution, Miami Beach

Local Institution, North Miami

Local Institution, Orlando

Local Institution, Plantation

Local Institution, Safety Harbor

Local Institution, South Miami

Local Institution, Tampa

Local Institution, Atlanta

Local Institution, Decatur

Local Institution, Chicago

Local Institution, Boston

Local Institution, Springfield

Local Institution, Kansas City

Local Institution, St Louis

Local Institution, East Orange

Local Institution, Newark

Local Institution, Union

Local Institution, Brooklyn

Local Institution, Manhasset

Local Institution, Mount Vernon

Local Institution, New York

Local Institution, Stony Brook

Local Institution, Valhalla

Local Institution, Philadelphia

Local Institution, Columbia

Local Institution, Austin

Local Institution, Dallas

Local Institution, Hampton

Local Institution, Milwaukee

Local Institution, Ponce

Local Institution, Rio Piedras

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY